Cibus (NASDAQ:CBUS) Announces Earnings Results

Cibus (NASDAQ:CBUS) issued its earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.10), FiscalAI reports. Cibus had a negative return on equity of 244.41% and a negative net margin of 2,258.89%.The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.70 million.

Here are the key takeaways from Cibus’ conference call:

• Revenue increased 35% year to date to $2.7 million, driven by Sustainable Ingredients collaboration agreements, while R&D and SG&A expenses declined by nearly $5 million year over year.
• Cibus expects additional scale-up orders for its biofragrance program in the second half of 2026 and estimates a potential $20 million–$40 million annual revenue opportunity when fully commercialized.
• The company pushed its expected initial Latin American rice commercialization from late 2027 to 2028; U.S. commercialization remains targeted for 2029, and royalties are not expected to begin until 2028.
• Cibus highlighted expanding rice partnerships, including Interoc’s increase from two traits to five, and described a potential rice royalty opportunity exceeding $200 million annually at peak adoption across the Americas.
• Cibus had $20.4 million in cash at June 30 and expects funding only into early Q1 2027, while its projected annualized net cash usage exiting 2026 increased to approximately $35 million as it invests in technology and personnel.

Cibus Stock Performance

Cibus stock traded down $0.13 during mid-day trading on Friday, reaching $1.77. 331,907 shares of the company were exchanged, compared to its average volume of 157,064. The firm has a market cap of $135.11 million, a P/E ratio of -1.07 and a beta of 1.61. The business has a fifty day moving average of $1.65 and a 200 day moving average of $1.97. Cibus has a 12-month low of $1.09 and a 12-month high of $4.19.

Institutional Investors Weigh In On Cibus

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after purchasing an additional 18,885 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Cibus in the 1st quarter valued at about $73,000. Qube Research & Technologies Ltd purchased a new position in shares of Cibus in the 2nd quarter worth approximately $39,000. Raymond James Financial Inc. lifted its position in Cibus by 31.0% during the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after acquiring an additional 12,722 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Cibus in the second quarter valued at approximately $207,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CBUS has been the subject of several recent research reports. Wall Street Zen upgraded Cibus from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings cut shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.